Recent developments and strategies of Ebola virus vaccines

Sharma, Ashish Ranjan; Lee, Yeon-Hee; Nath, Sudarshini; Lee, Sang-Soo

doi:10.1016/j.coph.2021.06.008

Cited by 15 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the phase 2 trials, a larger population is used to check the safety and immunogenicity of the vaccines formulated. Phase 3 studies evaluate the vaccine’s effectiveness during an epidemic, and phase 4 trial studies are used to monitor a vaccine’s safety after it has been released onto the market [ 40 ]. There are more than 70 clinical trials for vaccination against EBOV virus, out of which, only 2–3 received FDA approval by 2020.…”

Section: Human Clinical Trials Of Ebola Vaccinesmentioning

confidence: 99%

“…The vaccines worth mentioning that have successfully prevented further spread of the disease are the recombinant VSV-based vaccine (VSV-EBOV), Ad26-ZEBOV/MVA-BN-Filo vaccine, and GamEvac-Combi vaccine. The currently available vaccine candidates against EBOV virus include replicative vectored vaccines, non-replicative vectored vaccines, polypeptide vaccines, protein nanoparticle vaccines and DNA vaccines [ 40 ].…”

Section: Human Clinical Trials Of Ebola Vaccinesmentioning

confidence: 99%

“…Further, the Russian Federation’s Ministry of Health licensed the vaccine for use in humans. Phase 4 trials have been conducted in Guinea and Russia on a population of 2000 individuals to assess the efficiency, safety, and ability of the virus to initiate an immunogenic response [ 40 ]. The European Commission approved the marketing authorization for the Janssen Vaccines & Prevention heterologous primary and booster Ebola vaccine regimen in May 2020 to combat Ebola virus infection in both adults and children of atleast 1 year age.…”

Section: Human Clinical Trials Of Ebola Vaccinesmentioning

confidence: 99%

“…The current Ebola virus vaccines are INO-4201 (DNA vaccine), rVSVΔG-ZEBOV-GP, GamEvac-Combi, GamEvac-Lyo, rVSV N4CT1 EBOVGP1 (replicative vectored vaccine), Ad5-EBOV, Ad26.ZEBOV, MVA-BN-Filo, ChAd3, ChAd3-EBOZ, and MVA-VN-Filo, ChAd3, ChAd3-EBOZ, MVA-BN-Filo (non-replicative vectored vaccine), EpiVacEbola (polyepitope vaccine), and nanoparticle recombinant Ebola GP vaccine (protein nanoparticle vaccine) [ 40 ].…”

Section: Current Vaccine Considerationsmentioning

confidence: 99%

See 3 more Smart Citations

Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges

et al. 2023

View full text Add to dashboard Cite

The global outgoing outbreaks of Ebola virus disease (EVD) in different regions of Sudan, Uganda, and Western Africa have brought into focus the inadequacies and restrictions of pre-designed vaccines for use in the battle against EVD, which has affirmed the urgent need for the development of a systematic protocol to produce Ebola vaccines prior to an outbreak. There are several vaccines available being developed by preclinical trials and human-based clinical trials. The group of vaccines includes virus-like particle-based vaccines, DNA-based vaccines, whole virus recombinant vaccines, incompetent replication originated vaccines, and competent replication vaccines. The limitations and challenges faced in the development of Ebola vaccines are the selection of immunogenic, rapid-responsive, cross-protective immunity-based vaccinations with assurances of prolonged protection. Another issue for the manufacturing and distribution of vaccines involves post authorization, licensing, and surveillance to ensure a vaccine’s efficacy towards combating the Ebola outbreak. The current review focuses on the development process, the current perspective on the development of an Ebola vaccine, and future challenges for combatting future emerging Ebola infectious disease.

show abstract

Section: Human Clinical Trials Of Ebola Vaccinesmentioning

confidence: 99%

Section: Human Clinical Trials Of Ebola Vaccinesmentioning

confidence: 99%

Section: Human Clinical Trials Of Ebola Vaccinesmentioning

confidence: 99%

Section: Current Vaccine Considerationsmentioning

confidence: 99%

See 2 more Smart Citations

Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The high mortality rate and lack of effective interventional strategies for prevention or treatment of infection highlight the importance for developing a safe and effective EBOV vaccine to address this public health need. The currently licensed vaccines in the United States and Europe, under exceptional circumstances, all use viral vector platforms expressing the EBOV envelope glycoprotein (GP) antigen to stimulate an immune response [ 4 , 5 , 6 ]. GP is located on the surface of the virion and mediates attachment, fusion, and entry into target cells, and serves as the main target of a neutralizing antibody response [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal Challenge

Romanyuk

Marin

Janus

et al. 2022

JFB

View full text Add to dashboard Cite

Ebolavirus (EBOV) infection in humans is a severe and often fatal disease, which demands effective interventional strategies for its prevention and treatment. The available vaccines, which are authorized under exceptional circumstances, use viral vector platforms and have serious disadvantages, such as difficulties in adapting to new virus variants, reliance on cold chain supply networks, and administration by hypodermic injection. Microneedle (MN) patches, which are made of an array of micron-scale, solid needles that painlessly penetrate into the upper layers of the skin and dissolve to deliver vaccines intradermally, simplify vaccination and can thereby increase vaccine access, especially in resource-constrained or emergency settings. The present study describes a novel MN technology, which combines EBOV glycoprotein (GP) antigen with a polyphosphazene-based immunoadjuvant and vaccine delivery system (poly[di(carboxylatophenoxy)phosphazene], PCPP). The protein-stabilizing effect of PCPP in the microfabrication process enabled preparation of a dissolvable EBOV GP MN patch vaccine with superior antigenicity compared to a non-polyphosphazene polymer-based analog. Intradermal immunization of mice with polyphosphazene-based MN patches induced strong, long-lasting antibody responses against EBOV GP, which was comparable to intramuscular injection. Moreover, mice vaccinated with the MN patches were completely protected against a lethal challenge using mouse-adapted EBOV and had no histologic lesions associated with ebolavirus disease.

show abstract

A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico

Mahmoodi,

Amirzakaria,

Ghasemian

2024

Biotech and App Biochem

View full text Add to dashboard Cite

The emergence or reemergence of monkeypox (Mpox) and Ebola virus (EBOV) agents causing zoonotic diseases remains a huge threat to human health. Our study aimed at designing a multi‐epitope vaccine (MEV) candidate to target both the Mpox and EBOV agents using immunoinformatics tools. Viral protein sequences were retrieved, and potential nonallergenic, nontoxic, and antigenic epitopes were obtained. Next, cytotoxic and helper T‐cell (CTL and HTL, respectively) and B‐cell (BCL) epitopes were predicted, and those potential epitopes were fused utilizing proper linkers. The in silico cloning and expression processes were implemented using Escherichia coli K12. The immune responses were prognosticated using the C‐ImmSim server. The MEV construct (29.53 kDa) included four BCL, two CTL, and four HTL epitopes and adjuvant. The MEV traits were pertinent in terms of antigenicity, non‐allergenicity, nontoxicity, physicochemical characters, and stability. The MEV candidate was also highly expressed in E. coli K12. The strong affinity of MEV‐TLR3 was confirmed using molecular docking and molecular dynamics simulation analyses. Immune simulation analyses unraveled durable activation and responses of cellular and humoral arms alongside innate immune responses. The designed MEV candidate demonstrated appropriate traits and was promising in the prediction of immune responses against both Mpox and EBOV agents. Further experimental assessments of the MEV are required to verify its efficacy.

show abstract

Recent developments and strategies of Ebola virus vaccines

Cited by 15 publications

References 43 publications

Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges

Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges

Skin Vaccination with Ebola Virus Glycoprotein Using a Polyphosphazene-Based Microneedle Patch Protects Mice against Lethal Challenge

A novel multi‐epitope peptide vaccine targeting immunogenic antigens of Ebola and monkeypox viruses with potential of immune responses provocation in silico

Contact Info

Product

Resources

About